Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/181470
Title: | Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation |
Author: | López-Machado, Ana Díaz Garrido, Natalia Cano Fernández, Amanda Espina García, Marta Badía Palacín, Josefa Baldomà Llavinés, Laura Calpena Campmany, Ana Cristina Souto, Eliana B. García López, María Luisa Sánchez-López, E. (Elena) |
Keywords: | Síndromes de l'ull sec Oftalmopaties Sistemes d'alliberament de medicaments Agents antiinflamatoris Farmacologia ocular Dry eye syndromes Ophthalmopathies Drug delivery systems Antiinflammatory agents Ocular pharmacology |
Issue Date: | 15-Oct-2021 |
Publisher: | MDPI |
Abstract: | Abstract: Dry eye disease (DED) is a high prevalent multifactorial disease characterized by a lack of homeostasis of the tear film which causes ocular surface inflammation, soreness, and visual disturbance. Conventional ophthalmic treatments present limitations such as low bioavailability and side effects. Lactoferrin (LF) constitutes a promising therapeutic tool, but its poor aqueous stability and high nasolacrimal duct drainage hinder its potential efficacy. In this study, we incorporate lactoferrin into hyaluronic acid coated liposomes by the lipid film method, followed by high pressure homogenization. Pharmacokinetic and pharmacodynamic profiles were evaluated in vitro and ex vivo. Cytotoxicity and ocular tolerance were assayed both in vitro and in vivo using New Zealand rabbits, as well as dry eye and anti-inflammatory treatments. LF loaded liposomes showed an average size of 90 nm, monomodal population, positive surface charge and a high molecular weight protein encapsulation of 53%. Biopharmaceutical behaviour was enhanced by the nanocarrier, and any cytotoxic effect was studied in human corneal epithelial cells. Developed liposomes revealed the ability to reverse dry eye symptoms and possess anti-inflammatory efficacy, without inducing ocular irritation. Hence, lactoferrin loaded liposomes could offer an innovative nanotechnological tool as suitable approach in the treatment of DED. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/pharmaceutics13101698 |
It is part of: | Pharmaceutics, 2021, vol. 13, num. 10, p. 1698 |
URI: | https://hdl.handle.net/2445/181470 |
Related resource: | https://doi.org/10.3390/pharmaceutics13101698 |
ISSN: | 1999-4923 |
Appears in Collections: | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) Articles publicats en revistes (Bioquímica i Fisiologia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
715036.pdf | 11.41 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License